Lake Street Advisors Group LLC Boosts Stock Position in GSK plc (NYSE:GSK)

Lake Street Advisors Group LLC boosted its holdings in GSK plc (NYSE:GSK) by 24.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 8,298 shares of the pharmaceutical company’s stock after purchasing an additional 1,637 shares during the quarter. Lake Street Advisors Group LLC’s holdings in GSK were worth $284,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC grew its holdings in shares of GSK by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company’s stock worth $481,000 after purchasing an additional 3,405 shares during the last quarter. Pinnacle Associates Ltd. grew its holdings in shares of GSK by 6.2% during the third quarter. Pinnacle Associates Ltd. now owns 32,921 shares of the pharmaceutical company’s stock worth $1,346,000 after purchasing an additional 1,912 shares during the last quarter. JFS Wealth Advisors LLC grew its holdings in shares of GSK by 1,429.4% during the third quarter. JFS Wealth Advisors LLC now owns 29,426 shares of the pharmaceutical company’s stock worth $1,203,000 after purchasing an additional 27,502 shares during the last quarter. US Bancorp DE grew its holdings in shares of GSK by 12.2% during the third quarter. US Bancorp DE now owns 236,770 shares of the pharmaceutical company’s stock worth $9,679,000 after purchasing an additional 25,781 shares during the last quarter. Finally, Lincluden Management Ltd. grew its holdings in shares of GSK by 1.3% during the third quarter. Lincluden Management Ltd. now owns 66,001 shares of the pharmaceutical company’s stock worth $2,698,000 after purchasing an additional 833 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of GSK opened at $37.59 on Friday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a market capitalization of $77.90 billion, a price-to-earnings ratio of 23.64, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. The firm has a 50-day simple moving average of $34.99 and a 200-day simple moving average of $37.28. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, equities research analysts anticipate that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.18%. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is presently 98.74%.

Analysts Set New Price Targets

Several brokerages have issued reports on GSK. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.